In the meta-analysis involving a total of 9145 patients treated in the neoadjuvant setting, higher TILs in HER2+ BC were associated with larger benefits from NAChT combined with anti-HER2 therapy, expressed as higher pCR rate, longer DFS, and longer OS [35]. The gene discussed is ERBB2; the disease is breast cancer.